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Abstract
Background and Objectives The interplay between liver
metabolising enzymes and transporters is a complex process
involving system-related parameters such as liver blood per-
fusion as well as drug attributes including protein and lipid
binding, ionisation, relative magnitude of passive and active
permeation. Metabolism- and/or transporter-mediated drug–
drug interactions (mDDIs and tDDIs) add to the complexity of
this interplay. Thus, gaining meaningful insight into the
impact of each element on the disposition of a drug and
accurately predicting drug–drug interactions becomes very
challenging. To address this, an in vitro–in vivo extrapolation
(IVIVE)-linked mechanistic physiologically based pharma-
cokinetic (PBPK) framework for modelling liver transporters
and their interplay with liver metabolising enzymes has been
developed and implemented within the Simcyp Simulator.
Methods In this article an IVIVE technique for liver
transporters is described and a full-body PBPK model is
developed. Passive and active (saturable) transport at both
liver sinusoidal and canalicular membranes are accounted
for and the impact of binding and ionisation processes is
considered. The model also accommodates tDDIs involving
inhibition of multiple transporters. Integrating prior in vitro
information on the metabolism and transporter kinetics of
rosuvastatin (organic-anion transporting polypeptides
OATP1B1, OAT1B3 and OATP2B1, sodium-dependent
taurocholate co-transporting polypeptide [NTCP] and
breast cancer resistance protein [BCRP]) with one clinical
dataset, the PBPK model was used to simulate the drug
disposition of rosuvastatin for 11 reported studies that had
not been used for development of the rosuvastatin model.
Results The simulated area under the plasma concentra-
tion–time curve (AUC), maximum concentration (Cmax)
and the time to reach Cmax (tmax) values of rosuvastatin over
the dose range of 10–80 mg, were within 2-fold of the
observed data. Subsequently, the validated model was used
to investigate the impact of coadministration of cyclospor-
ine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP,
on the exposure of rosuvastatin in healthy volunteers.
Conclusion The results show the utility of the model to
integrate a wide range of in vitro and in vivo data and
simulate the outcome of clinical studies, with implications
for their design.
1 Introduction
As the proportion of candidate drugs within the Biophar-
maceutical Drug Disposition Classification System
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(BDDCS) class 2–4 entering development increases, it is
becoming evident that transporter-mediated drug–drug
interactions (tDDIs) may pose challenges for regulatory
approval and clinical practice [1, 2]. So it is not surprising
that many regulatory agencies are now requesting investi-
gation of transporter effects in vivo whenever they are
likely to be clinically relevant [3, 4]. Considering the
number of transporters in the body, including the gut, liver,
kidney, heart and brain, investigation of tDDIs can be
complicated, difficult to interpret and costly.
The contribution of the organic anion-transporting
peptide (OATP) family of solute carriers (SLCs) to the
hepatic elimination of many drugs and associated drug–
drug interactions (DDIs) is significant [5, 6]. This may lead
to an increase in the susceptibility of a drug to a tDDI. This
is particularly the case for statins (HMG-CoA reductase
inhibitors), as many patients taking these drugs for lipid
lowering have co-morbidities and are co-prescribed a
number of other medications [7]. Rosuvastatin is a rela-
tively hydrophilic statin (Class 3 according to the BDDCS)
with a low oral bioavailability of *20 % [8]. With limited
metabolism (*10 %) occurring mainly via cytochrome
P450 (CYP) 2C9 and uridine diphosphate glucuronosyl-
transferase (UGT) 1A1 [9–12], the main excretion path-
ways of rosuvastatin are mediated via the biliary and renal
routes [8, 13]. Despite a low passive diffusion into hepa-
tocytes [14], rosuvastatin is extensively distributed into the
liver, its site of action [15, 16]. This is mainly due to active
uptake of rosuvastatin by OATP1B1, OATP1B3 and
OATP2B1, as well as the sodium-dependent taurocholate
co-transporting polypeptide (NTCP) [17, 18]. On the can-
alicular side, rosuvastatin is excreted into the bile via the
breast cancer resistance protein (BCRP) [17, 19]. An
increase in the plasma area under the concentration–time
curve (AUC) of rosuvastatin was observed in patients pre-
treated with gemfibrozil, an inhibitor of OATPs [20].
Similarly, rosuvastatin AUC and the maximum plasma
concentration (Cmax) were increased by 7- and 10-fold,
respectively, in heart transplant recipients (compared with
healthy volunteers [HVs]) on an anti-rejection regimen
including the immunosuppressant cyclosporine (ciclospo-
rin), which is an inhibitor of OATPs and NTCP [21].
Application of in vitro–in vivo extrapolation (IVIVE), a
‘‘bottom-up’’ approach, in conjunction with physiologi-
cally based pharmacokinetic (PBPK) modelling under a
mechanistic systems biology approach can help to predict
complex DDIs and also inform the design of clinical
studies in HVs or patient populations [22, 23]. The model
that is incorporated within the Simcyp Population Based
Simulator [24] allows investigation of metabolism and
transport interplay within the liver and can also be used for
quantitative prediction of metabolism-mediated drug–drug
interactions (mDDIs) and tDDIs. In this study, we present
an IVIVE framework for scaling in vitro liver transporter
kinetic data to in vivo. We account for the impact of drug
ionisation on extra- and intracellular water (EW and IW)
concentrations within the permeability-limited liver (PerL)
model and present equations to estimate the unbound
concentration fractions in EW and IW compartments based
on tissue composition and drug physicochemical data. We
demonstrate application of the approach by describing the
development of a PBPK model for rosuvastatin, incorpo-
rating active uptake into the liver via OATP1B1,
OATP1B3, OATP2B1 and NTCP, in addition to excretion
of the drug into the bile by BCRP. The impact of
co-administration of cyclosporine is also investigated.
2 Methods
2.1 Model Theory and Development
2.1.1 Physiologically Based Pharmacokinetic Models
A schematic structure of the PBPK model is shown in
Fig. 1. It comprises 15 compartments, where all compart-
ments apart from the liver and gut are well-stirred models.
The gastrointestinal tract is modelled using the Advanced
Dissolution, Absorption and Metabolism (ADAM) model
[25]. The model accounts for interplay of gut metabolism
and transport and also the heterogeneity of distribution of
enzymes and transporters along the gastrointestinal tract
[26, 27]. The typical tissue volumes, tissue density values
and tissue blood flows are provided in the Electronic
Supplementary Materials.
2.1.2 Perfusion Versus Permeability-Limited Models
In PBPK models tissues/organs are generally represented
as perfusion-limited models, where it is assumed that drugs
passively diffuse into tissue water and reach equilibrium
instantaneously and distribute homogeneously into the
available space [28]. Therefore, for a non-eliminating tis-
sue, a single-compartment well-stirred model can be used
to describe the distribution process using the following








where VT, QT and CT are the tissue volume, blood flow and
concentration, respectively. CAR is the arterial blood con-
centration, Kp is the tissue-to-plasma partition coefficient
and B:P is the blood-to-plasma ratio. For modelling
transporter functionality or scenarios where the tissue
plasma membranes limit the drug distribution from the
extracellular water (EW) into cells these models cannot be
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used. Instead multi-compartment permeability-limited
models are used to describe the distribution process. Fig-
ure 1 shows a schematic of this model for the liver where
two membrane sides (sinusoidal and canalicular) are con-
sidered. The proposed PerL model is divided into three
compartments: vascular space (VS), EW and IW. Many
processes are considered simultaneously, including protein
and lipid binding and ionisation, all of which are assumed
to be instantaneous, and active and passive transport in and
out of the compartments.
The following assumptions apply to the PerL model:
• The vascular and extracellular compartments are in
instantaneous equilibrium, although the total concen-
tration in these compartments can be different [29].
• Only un-ionised and unbound species can passively
permeate through the plasma membrane [30] and
transporters act only on unbound drug.
• The movement of the unbound un-ionised species from
the VS to the EW is not a rate-limiting process.
• Passive permeability at the canalicular side of the liver
plays a negligible role in biliary secretion.
These assumptions underpin the need to determine
unbound extracellular and intracellular concentrations.
Unbound fractions in these milieus are usually unknown or
challenging to measure in vitro. Thence, having models to
predict these fractions based on the physicochemical
properties of the compound and tissue compositions is
desirable. The development of mechanistic equations
incorporating compound lipophilicity, binding of com-
pound to plasma and tissue macromolecules, and levels of
phospholipids and neutral lipids in plasma and tissues has
improved prediction of the tissue distribution of many
compounds [31, 32]. These in silico models have been
further developed to account for both protein binding in the
Fig. 1 PBPK model showing both the ADAM and PerL model. The
ADAM module represents the gastrointestinal tract as compartments
based upon their physiological and anatomical attributes, hence the
relationship between permeability, metabolism and dissolution,
amongst other factors, can be assessed quantitatively. Once the drug
has passed into the portal vein the drug’s kinetics are described by a
full PBPK model using the PerL model along with the rest of the well-
stirred compartments. ADAM Advanced Dissolution, Absorption and
Metabolism, BCRP breast cancer resistance protein, EHC extrahe-
patic circulation, fuIW unbound fraction in intracellular water, IV
intravenous, KtEW-in and KtIW-out overall transport rate in and out of
the intracellular water, respectively, NP, NL and AP neutral
phospholipids, neutral lipids and acidic phospholipids, respectively,
P plasma protein, PBPK physiologically based pharmacokinetic, Perl
permeability-limited liver, PO oral, ?ve and -ve represent the drug
in ionised form, i.e. with and without a valence electron
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EW and binding of strong bases (drug acid-ionisation
constant [pKa] [7.0) to acidic phospholipids [30, 33, 34].
Steady-state conditions and instantaneous equilibrium of
the unbound drug at membranes are assumed. Using the
same approach [30, 33, 34], and based on the aforemen-
tioned assumptions, equations have been developed to
estimate unbound concentrations of drug in IW and EW
and to predict transporter functionality in the liver (see the
Electronic Supplementary Materials for the derivations).
2.1.3 Liver Compartmental Concentrations
The differential equations for the liver compartments are
developed in a general form and can consider any number
of efflux and/or update transporters at each of the liver
membranes. Assuming the transporter functionality can be
described using a Michaelis–Menten equation, Jmax
(in vivo maximum rate of transporter-mediated efflux or
uptake) and Km (Michaelis–Menten constant) are the
required parameters to determine the transport rate of the
drug across membranes. The drug passive permeation is
determined by the passive diffusion parameter, CLint,PD,
which is equal to the permeability surface product.
Berezhkovskiy [29] proposed using the effective organ
volume rather than actual volume. This can be particularly
important for drugs with high blood-to-plasma ratio and in
tissues with a high proportion of VS. Therefore, the
effective extracellular tissue volume (VEW-eff), which is a
combination of the extracellular volume and the VS, is
considered, as shown in Eq. 2:
VEWeff ¼ VEW þ VVS
KEW:B
ð2Þ
where VEW is the EW volume and KEW:B is the quotient of
total EW concentration and the total blood concentration in
the tissue VS (see Electronic Supplementary Materials).
Volume of the VS (VVS) represents 15 % of the liver
volume [35]. As a result, the unbound extracellular



























Km;Sin;m þ CuIW ð3Þ
where QPV and QAR are the portal vein and arterial blood
flows, respectively, CAR and CPV are the arterial and portal
vein concentrations, respectively, ‘‘Sin’’ represents the
sinusoidal membrane, n and m represent the total number
of uptake and efflux transporters involved in the drug
transport, and ‘‘uptake’’ and ‘‘efflux’’ represent the
transport functionality. CuEW and CuIW represent the
unbound EW and IW concentrations, respectively, and
fuEW is the extracellular unbound fraction. W and a for a
monoprotic base are 1 þ 10pKapHEW and 10pKapHIW where
pKa is the drug acid-ionisation constant, and pHEW and
pHIW are the EW and IW pH values, respectively. For other
drug charge types these equations can be defined similarly
based on the compound charge type using the Henderson–
Hasselbalch equation (see Electronic Supplementary
Materials). Similarly, the intracellular unbound






























Km;Can;i þ CuIW ð4Þ
where ‘Can’ refers to the canalicular side and I represents
the total number of efflux transporters pumping the drug
into bile ducts. fuIW is the intracellular unbound fraction,
fIW is the intracellular volume fraction, VLiv is the liver
volume Vmax is the in vivo maximum metabolism rate and
Km is the metabolism Michaelis–Menten constant for each
of the enzymes that metabolise the drug. As uptake trans-
porters on the canalicular membrane have not been repor-
ted for drugs, this is not considered.
2.1.4 In Vitro–In Vivo Extrapolation of Transporter
Kinetic Parameters
Assuming that a Michaelis–Menten equation can describe
uptake or efflux of drugs in and out of cells then Jmax (in
pmol/min/million hepatocyte) and Km (in lmol/L) are
needed to determine CLint,T (transport clearance in lL/min/
million hepatocyte) as follows (Eq. 5):
CLint;T ¼ Jmax
Km þ Cu ð5Þ
where Cu is the unbound concentration at the transporter
site. Hence, for the liver uptake transporters Cu is the
unbound concentration in the EW and for efflux
transporters it is the unbound concentration in the IW. In
the differential equations described in the previous section,
Jmax represents the in vivo value for maximum flux rate of
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the whole liver and thus this in vitro value needs to be
scaled by the following scaling factor (SF) [Eq. 6]:
SF ¼ HPGL  LiverWt  REF  60  106 ð6Þ
where HPGL is the hepatocellularity, i.e. the hepatocytes
per gram of liver [36], LiverWt is the liver weight [37] and
REF is the relative expression factor, which can also be
replaced by a relative activity factor (RAF), and 60 9 10-6
is the unit change to convert the CLint,T to L/h. The liver
REF or RAF values are determined as the ratio of the
transporter expression and/or functionality in vivo relative
to the corresponding value in the relevant in vitro system
(e.g. hepatocyte or expression systems such as HEK
[human embryonic kidney] cells) according to the
following equation (Eq. 7):
REF ¼ in vivo expression=in vitro expression ð7Þ
The same approach is applied to scale up the CLint,PD
(mL/min/millions of hepatocyte) value; therefore, the SF
for passive permeability (SFPD) across the hepatocyte is
defined by Eq. 8:
SFPD ¼ HPGL  LiverWt  60  103 ð8Þ
2.1.5 Transporter-Mediated Drug–Drug Interactions
Drug–drug interactions can occur for both metabolising
enzymes and transporters. For cytochrome P450 (CYP)
enzymes, competitive and/or time-dependent inhibition and
induction are accounted for as previously explained [38–40].
Here, we describe equations relating to tDDIs, assuming
that the mechanism of inhibition is competitive. Equation 9
can be used to modify transporter-mediated intrinsic
clearance values:
CLint; Tinh ¼ Jmax




where CLint,T-inh is the transporter-mediated intrinsic
clearance in the presence of an inhibitor, the ‘‘inh’’ suffix
refers to the inhibited value, Iu is the unbound
concentration at the binding site of a transporter and Kui
is the unbound concentration of the inhibitor that supports
half-maximal inhibition (corrected for non-specific
binding). In the case of multiple inhibitors, it is assumed
that all inhibitors are acting via the same mechanism (or
the overall effect is similar) on each transporter. Therefore,
the overall effect can be modelled using the same approach











where j represents the inhibitor index of either the parent
drug, its metabolites or both, and C is the victim drug
concentration at the transporter site. There are literature
reports that support such assumptions [42]. Further, the
developed model handles metabolism- and transporter-
mediated DDIs for both victim and perpetrator drugs;
hence, drugs can mutually affect each other.
2.2 Development of the Rosuvastatin Model
The sub-models and differential equations described in the
previous sections were used to develop a full PBPK model,
including permeability-limited diffusion into the liver to
describe the disposition of rosuvastatin. The absorption of
rosuvastatin from solution was defined using the ADAM
model.
2.2.1 Data Used for Simulations of Rosuvastatin
Pharmacokinetics
In vitro and pharmacokinetic parameters for rosuvastatin
were collated from data in the literature (Table 1). Where
data from more than one source were available for the same
parameter, weighted means were calculated based on the
number of observations reported. Details relating to some
of the key input parameters are given in the following
sections.
2.2.2 Whole-Organ Metabolic Clearance
Rosuvastatin undergoes only minor metabolism and thus
these enzyme kinetics have not been characterised quan-
titatively in vitro. Therefore, a global value of net intrinsic
hepatic clearance (CLuint,H) was back-calculated from
in vivo clearance (CLiv,B) using Eq. 11:
CLuint;H ¼ QH  CLH;B
fuB  ðQH  CLH;BÞ ð11Þ
where fuB = fu/(B:P) (values were 0.107 and 0.625 for fu
and B:P, respectively), QH is hepatic blood flow (90 L/h)
and CLH,B is the hepatic metabolic clearance in blood
(50.9 L/h) derived from CLiv,B (78.1 L/h) after subtraction
of CLR,B (renal clearance with respect to blood, 27.2 L/h).
The estimated net CLuint,H of 648.2 L/h was divided by an
average liver weight of 1,648 g [37], a microsomal protein
per gram of liver (MPPGL) value of 39.8 mg of micro-
somal protein/g liver [52] to obtain a value of 174 lL/min/
mg protein. As the derived value is a composite of trans-
port and metabolism, 10 % (17.4 lL/min/mg protein) was
assigned as the metabolism component for human liver
microsomes (HLM) based on previously published data [8,
13, 53].
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Table 1 Parameter values used for the rosuvastatin simulations
Parameter Value Reference/comments
Molecular weight (g/mol) 481.54
fu—experimental 0.107 [8, 43]
Blood-to-plasma ratio (B:P)—experimental 0.625 [8, 43]
Log of the octanol:water partition coefficient
(logPo:w)—experimental
2.4 [44]
Compound type Monoprotic acid Marvin Sketch 5.4.0.1
pKa 4.27 [43, 45]
Main plasma binding protein HSA (human serum albumin)
Absorption
Model ADAM
Caco-2 permeability [Papp,caco-2(7.4:7.4) (10
-6 cm/s)] 3.395 [46]
Reference compound Propranolol
Reference Papp,caco-2(7.4:7.4) (10
-6 cm/s) 20 [46]
fa—predicted 0.66 Based on Caco-2 data
fa—observed 0.55 [8]
ka (h
-1)—predicted 0.35 Based on Caco-2 data
ka (h
-1)—observed 0.46–0.78 Range [20, 47]
Distribution
Model Full PBPK
Vss (L/kg)—predicted 0.227 Rodgers and Rowland method;
see text for details
Vss (L/kg)—observed 1.73 [8]
Elimination
CLiv (L/h) 48.78 [8]
CLint (lL/min/mg protein) 17 Calculated using the retrograde model
CLR (L/h) 17 Meta-analysis [8, 48]
Transport (active and passive)
Intestinal efflux intrinsic clearance
CLint,T,BCRP (lL/min/cm
2) 35
Intestinal BCRP REF (User) 1
Hepatic efflux intrinsic clearance
CLint,T,OATP1B1 (lL/min/million hepatocytes) 109 See text for details; [17]
Hepatic OATP1B1 REF (User) 1
CLint,T,OATP1B3 (lL/min/million hepatocytes) 36 See text for details; [17]
Hepatic OATP1B3 REF (User) 1
CLint,T,NTCP (lL/min/million hepatocytes) 78 See text for details; [17, 18]
Hepatic NTCP REF (User) 1
CLint,T,BCRP (lL/min/million hepatocytes) 1.23 [49]
Hepatic BCRP REF (User) 1
CLbile (L/h)—predicted 15 Using above data
CLbile (L/h)—observed 4–195 [15, 50]
Passive intrinsic clearance at sinusoidal membrane
CLint,PD (mL/min/million hepatocytes) 0.0025 [51]
For CLR—these data were obtained from a meta-analysis of clinical data. The cited value is the weighted mean (accounting for the number of subjects in
each study) of the reported values
Values in bold were refined using in vivo information
ADAM Advanced Dissolution, Absorption and Metabolism, BCRP breast cancer resistance protein, CLbile biliary clearance, CLint human liver microsome
intrinsic clearance, CLint,PD passive diffusion parameter, CLiv in vivo systemic clearance, CLR renal clearance, fa fraction absorbed, fu fraction unbound in
plasma, ka absorption rate constant, OATP organic-anion transporting polypeptide, NTCP sodium-dependent taurocholate co-transporting polypeptide,
REF relative expression factor, Vss volume of distribution at steady state
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2.2.3 Permeability Data
Permeability data obtained using Caco-2 cells (Papp) for
rosuvastatin (3.395 9 10-6 cm/s) was calibrated using
propranolol (20 9 10-6 cm/s) and then extrapolated to an
effective permeability in human (Peff,man) of
0.855 9 10-4 cm/s using the default regression equation
within the Simcyp Simulator. It was assumed that Peff,man
was consistent across all segments of the intestine includ-
ing the duodenum, jejunum, ileum and colon.
2.2.4 Kinetic Data for Rosuvastatin Transport
Active and passive kinetic transport data for the hepatic
sinusoidal uptake (OATP1B1, OATP1B3 and NTCP) and
canalicular efflux (BCRP) of rosuvastatin were available. It
is not always possible to recover observed drug plasma
concentration–time profiles accurately purely from the
‘bottom-up’ using physicochemical, in vitro permeability
and metabolism/transport data. To accommodate inherent
uncertainty, the parameter estimation (PE) module within
the Simcyp Simulator may be used to optimise key
parameter values. This provides a link between the ‘bot-
tom-up’ and ‘top-down’ pharmacokinetic modelling para-
digms by utilising available in vivo data to modify
parameters based purely on in vitro studies. The simula-
tions then move forward more effectively to predict the
impact of specific perturbations of drug kinetics as a con-
sequence of a DDI.
Preliminary simulations indicated that the experimental
transporter kinetic data were not able to recover the
observed profiles of rosuvastatin. Thus, a global intrinsic
clearance for the active hepatic uptake (global CLint,T) of
rosuvastatin was obtained using the PE module within the
Simcyp Simulator and the observed plasma concentration–
time data from Martin and co-workers [8] following
intravenous administration of rosuvastatin in HVs. Other
parameters were fixed to the in vitro values (Table 1), and
optimisation was done using the Nelder–Mead minimisa-
tion method and weighted least squares algorithm. A global
CLint,T of 222 lL/min/million cells was obtained for
hepatic uptake of rosuvastatin. This was apportioned to
OATP1B1, OATP1B3 and NTCP, based on the relative
contributions of each of the transporters to the active
uptake of rosuvastatin in vitro. According to the study of
Kitamura and co-workers [17], the contribution of
OATP1B1 to the active hepatic uptake of rosuvastatin in
human hepatocytes is on average about 49 %. Using
sandwich culture human hepatocyte (SCHH), Ho and
co-workers [18] estimated that the percentage contribution
of NTCP is about 35 %. It was assumed that the remaining
16 % represented the transporter-mediated uptake of
rosuvastatin into the liver via OATP1B3. Thus, CLint,T
values of 109, 36 and 78 lL/min/million cells were
assigned to hepatic uptake of rosuvastatin by OATP1B1,
OATP1B3 and NTCP, respectively (Table 1). It has been
reported that OATP2B1 also contributes to the uptake of
rosuvastatin. However, since modelling this transporter
requires more sophisticated models that account for ion
gradients and multiple binding sites, its contribution was
combined with that of OATP1B3. As the data were derived
from in vivo data, no REFs were applied (the REFs/RAFs
were set to 1). The hepatic canalicular efflux contribution
was recalculated from in vitro data in SCHH (CLint biliary
3.39 mL/min/kg [49]) using 107 9 106 HPGL and 25.7 g
of liver per kg bodyweight and assigned to BCRP. A value
of 1.23 ((3.39/25.7)/107) 9 1,000) lL/min/million hepa-
tocytes was obtained.
Although rosuvastatin has been shown to be a substrate
of intestinal BCRP in vitro [19], no quantitative data were
available. Therefore, a sensitivity analysis was performed
to obtain estimates of the intestinal CLint,T of BCRP using
observed rosuvastatin time to Cmax (tmax) and Cmax for a
given dose of 40 mg [21, 54]. A value of 35 lL/min/cm2
was able to recover observed tmax and Cmax values and was
thus applied in further simulations.
2.2.5 Data Used for Simulations of Cyclosporine
Pharmacokinetics
In vitro and pharmacokinetic parameters for cyclosporine
were taken from data in the literature (Table 2). Cyclo-
sporine is an inhibitor of OATP1B1, OATP1B3, NTCP and
BCRP; IC50 (the concentration that inhibits 50 % of the
transporter activity) values of 0.1, 0.05, 4.5 and 2.0 lmol/L,
respectively, have been generated in the same laboratory
and reported by Clarke and co-workers [55, 56]. The
OATP1B1 inhibition constant (Ki) is approximately 10-fold
higher than that reported previously by Amundsen and
co-workers [57]. It has been demonstrated that the value
derived in the latter study (0.014 lmol/L) can be applied
successfully for prediction of tDDIs involving OATP1B1
[58, 59]. Thus, all of the IC50 values reported by Clarke and
co-workers [55, 56] were converted to Ki values and cali-
brated using the 10-fold factor derived for OATP1B1 to
retain the same relative inhibitory potencies; final values of
0.014, 0.007, 0.28 and 0.07 lmol/L were used for
OATP1B1, OATP1B3, NTCP and BCRP, respectively. In
the full PBPK model of cyclosporine a well-stirred liver
model was used; therefore, the surrogate inhibitory con-
centrations according to Table 3 were applied.
2.2.6 Simulations
All simulations were performed using the Simcyp Simulator
(version 12, release 2). The program allows facile
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extrapolation of in vitro enzyme kinetic data in both liver and
intestine, to predict pharmacokinetic changes in vivo in
virtual populations. Genetic, physiological and demographic
variables relevant to the prediction of DDIs are generated for
each individual using correlated Monte-Carlo methods and
equations derived from population databases obtained from
literature sources. To ensure that the characteristics of the
virtual subjects were matched closely to those of the subjects
studied in vivo, numbers, age range and sex ratios were
replicated. The following simulations were performed:
• Ten virtual trials of HVs (subject number, age range, %
female according to Table 4) receiving a single oral
dose of rosuvastatin 10, 20, 40 or 80 mg were
generated. The simulated profiles for rosuvastatin were
compared with observed data from 11 independent
pharmacokinetic studies (Table 4).
Table 2 Parameter values used for the cyclosporine simulations
Parameter Value Reference/comments
Molecular weight (g/mol) 1,202
fu—experimental 0.0365 [60]
Blood/plasma ratio (B:P)—experimental 1.36 [31]




Main plasma binding protein HSA (human serum albumin)
Absorption
Model ADAM
Effective permeability (Peff,man) (10




0.001 Permeability in the colon was set to *0 in order to
achieve an fa of \1 (consistent with observed data)
fa—predicted 0.857 Based on observed Peff,man
ka (h
-1)—predicted 0.679 Based on observed Peff,man
ka (h
-1)—observed 0.68–1.6 Range [64, 65]
Distribution
Model Full PBPK Rodgers and Rowland method; see text for details
Vss (L/kg)—predicted 1.7 When applying Kp liver and Kp spleen
Vss (L/kg)—observed 1.48 [64, 66]
Liver partition coefficient (Kp) 11 [67]
Spleen partition coefficient (Kp) 7.7 [67]
Elimination
CLiv (L/h) 24.07 [64, 66]
Intrinsic clearance (CLint CYP3A4) (lL/min/pmol CYP) 2.64 Calculated using the retrograde approach
CLR (L/h) 0.024 Applying fe (fraction of drug excreted) of 0.001
(Sandimmune Prescribing Information) to a
systemic clearance of 24.07 L/h
Interaction
Ki—intestinal BCRP (lmol/L) 0.28 See text for details; [56, 57]
Ki—hepatic OATP1B1 (lmol/L) 0.014 [56, 57]
Ki—hepatic OATP1B3 (lmol/L) 0.007 See text for details; [56, 57]
Ki—hepatic NTCP (lmol/L) 0.63 See text for details [56, 57]
Ki—hepatic BCRP (lmol/L) 0.28 See text for details [56, 57]
ADAM Advanced Dissolution, Absorption and Metabolism, BCRP breast cancer resistance protein, CLiv in vivo systematic clearance, CLR renal clearance,
CYP cytochrome P450, fa fraction absorbed, fu fraction unbound in plasma, ka absorption rate constant, Ki concentration of inhibitor that supports half-
maximal inhibition, Kp tissue-to-plasma partition coefficient, NTCP sodium-dependent taurocholate co-transporting polypeptide, OATP organic anion-
transporting peptide, PBPK physiologically based pharmacokinetic, Vss volume of distribution at steady state
Table 3 Interacting concentrations used depending on the selected






Efflux IuIW ILiv fu/(Kp Liv)
Uptake IuEW ILiv fu/(Kp Liv)
EW extracellular water, I perpetrator concentration affecting other
victim moieties, fu fraction unbound in plasma of the perpetrator, IW
intracellular water, Kp tissue-to-plasma partition coefficient, Liv liver,
u unbound
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• Ten virtual trials of ten HVs aged 30–65 years (0.11 %
female; one female subject) receiving multiple oral
doses of rosuvastatin 10 mg co-administered with oral
cyclosporine (200 mg twice daily) for 10 days were
generated. The simulated profiles for rosuvastatin were
compared with observed data [21, 54].
3 Results
Simulated rosuvastatin plasma concentration–time profiles
following oral doses (10–80 mg) were reasonably consis-
tent with observed data from 11 independent clinical
studies in HVs (Fig. 2). The individually simulated profiles
matching each study and the comparison to observed data
are shown in the Electronic Supplementary Material. It
should be noted that over the dose range 10–80 mg, the
observed data were highly variable; however, apparent
total oral clearance (CL/F), Cmax and tmax ratios for pre-
dicted versus observed data were generally within 2-fold.
Following oral administration, the median predicted AUC
from time zero to time t (AUCt) values of rosuvastatin at
10 mg ranged from 23.95 to 39.70 ng/mLh for the ten
simulated trials (mean 35.16, median 32.06, geometric
mean 31.82) using 50 % male subjects between 20 and
50 years of age; the observed geometric mean values were
31.6 [54] and 45.9 ng/mLh [68]. Median predicted AUCt
values of rosuvastatin at 20 mg ranged from 47.79 to
79.37 ng/mLh for the ten simulated trials (mean 70.06,
median 63.99, geometric mean 63.45); the observed geo-
metric mean value was 56.8 ng/mLh [54]. Median pre-
dicted AUCt values of rosuvastatin at 40 mg ranged from
95.58 to 158.74 ng/mLh for the ten simulated trials (mean
140.12, median 127.97, geometric mean 126.91); the
observed geometric mean values were 98.2 [54], 165 [8]
and 216 ng/mLh [14]. Mean predicted AUCt values of
rosuvastatin at 80 mg ranged from 198.03 to 342.74 ng/
mLh for the ten simulated trials (mean 284.57, median
252.29, geometric mean 255.76); the observed geometric
mean values were 253 [69], 268 [54], 325 [70], 397 [68]
and 410 ng/mLh [20].
Simulated rosuvastatin plasma concentration–time pro-
files in the absence and presence of cyclosporine (200 mg
twice daily) following 10 days of rosuvastatin administra-
tion (10 mg multiple dose) in HVs are shown in Fig. 3.
Predicted median AUCt and Cmax ratios for the ten virtual
trials ranged from 1.45 to 1.68 and 2.73 to 3.62, respec-
tively (Fig. 3). Although HV data weren’t available for
direct comparison, clinical data indicated that the AUC
from time zero to 24 h (AUC24) and Cmax values were
increased 7.1- and 10.6-fold, respectively, in stable heart
transplant recipients ([6 months after transplant) on an
anti-rejection regimen including cyclosporine compared to
HV [21]. Sensitivity analysis of different elimination pathways
suggests the hepatic uptake transporter is the most sensitive
factor in rosuvastatin elimination (data not shown). Fig-
ure 4 shows the rosuvastatin unbound concentrations in the
liver extracellular (CuEW) and intracellular (CuIW) com-
partments in absence and presence of cyclosporine for the
simulated population. The figure shows that there is sig-
nificant difference between CuEW and CuIW and the dif-
ferential impact of transporter-mediated inhibition in the
extracellular and intracellular compartments.
4 Discussion
4.1 Model Development and Unbound Fractions
To model pravastatin pharmacokinetics in humans,
Watanabe and co-workers used a PBPK model where the liver
was divided into five units consisting of the extracellular
and subcellular compartments [71, 72]. The units were
connected in tandem by blood flow rate to mimic the liver
dispersion model. They argued that, especially for high
extraction drugs, the well-stirred model underestimates the
hepatic clearance compared with the parallel tube and
dispersion models, and the difference becomes greater
when active uptake increases. The unbound fraction in the
extracellular compartment and subcellular compartments
was assumed to be the same as the unbound fraction in
blood and the tissue unbound fraction (measured in rats),
respectively.
Jones and co-workers [43] also used PBPK models with
a liver permeability model to predict the pharmacokinetics
of seven OATP substrates using in vitro data generated








n % female Reference
1 10 22–42 11 0 [68]
2 10 31–60 18 0 [54]
3 20 31–60 9 0 [54]
4 40 31–60 9 0 [54]
5 40 21–51 10 0 [8]
6 40 21–39 36 13.9 [14]
7 80 22–44 11 0 [69]
8 80 25–56 14 0 [68]
9 80 29–51 14 0 [70]
10 80 31–60 18 0 [54]
11 80 35–47 20 15 [20]
n number of subjects in each study, % female the female percentage in
the study
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from SCHH. As per Watanabe et al. [71], they divided the
liver into five units and used measured unbound fractions
from in vitro experiments. Measuring unbound extracel-
lular and intracellular fractions is a laborious and complex
process and, thus, it is highly desirable to predict these
values at early stage of drug development. Recently, the
advent of more mechanistic approaches to assess drug
distribution into tissues has led to the development of
methods for prediction of unbound fractions using physi-
cochemical properties [30–32, 34]. The Rodgers and
Rowland equations improved Kp predictions largely due to
the incorporation of distribution processes related to drug
ionisation, an issue that was not addressed in earlier
equations [34]. These methods were mainly developed
assuming steady-state conditions and instantaneous equi-
librium of the unbound drug at membranes. However,
researchers have tried modifying these equations to
account for non-equilibrium conditions to develop models
that describe transporter functionality in different organs
such as the liver, brain and heart [73, 74]. Fenneteau and
co-workers [73] proposed mechanistic transport-based
models to investigate the impact of P-glycoprotein-medi-
tated efflux in mouse brain and heart. Their model assumed
that transport occurs at the capillary membrane. They
developed an equation for estimating the tissue unbound
fraction where they assumed CuEW and Cup (unbound
concentration in plasma) are equal and CuIW and Cup only
differ by an ionisation factors. Nevertheless, these
assumptions are only valid for passive permeability and
instantaneous equilibrium, which are not applicable in this
case. Poirier and co-workers [74] used a similar approach
to simulate the plasma concentration of napsagatran and
fexofenadine in rats and that of valsartan in humans [75].
They predicted fuIW using the method by Poulin and Theil
[31, 32] and fuEW using the method by Rodgers and
Rowland [30, 34]. However, their fuIW equation for the
permeability-limited model was independent of fIW.
Our proposed liver model (PerL) and the unbound
fraction prediction equations account for the processes
involved in drug transport at the liver membranes. Obvi-
ously, their validity should be assessed for a range of
compounds. It should be noted that these equations are
mainly developed to provide predictions during the dis-
covery and early stages of drug development when mea-
sured values are not available. Generally, to increase
confidence in pharmacokinetic predictions it is recom-
mended these values be obtained from in vitro experiments
whenever possible [76].
4.2 Development of the Rosuvastatin Model
In this study, we have presented a PBPK model for rosu-
vastatin, incorporating gut efflux by BCRP and active
uptake into the liver via OATP1B1, OATP1B3
(OATP2B1) and NTCP, in addition to excretion of the drug
into the bile by BCRP. Although the model was able to
recover the observed data in most cases, for some studies
the absorption delay was not captured. The delay may be a
a b
c d
Fig. 2 Simulated and observed
plasma concentration–time
profiles of rosuvastatin in
healthy volunteers following the
oral administration of a 10 mg,
b 20 mg, c 40 mg and d 80 mg.
The black line represents the
mean concentration for the
simulated population (n = 100,
20–50 years, health volunteers,
50 % female). The light and
dark grey lines represent the
upper (95 %) and lower (5 %)
percentile concentrations of the
simulated populations,
respectively. The markers
denote mean values from the
clinical studies [8, 14, 20, 54,
68–70]
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result of increasing solubility along the intestine due to pH
changes or, alternatively, rosuvastatin may be a substrate of
other efflux transporters that have higher expression in the
proximal part of the intestine, e.g. MRP2 (multi-drug
resistance protein 2). However, as there was considerable
variability in clinical data across doses and the rosuvastatin
model was able to recover observed data in most cases, the
model was considered to be reasonably robust for assess-
ment of the magnitude of interaction with cyclosporine, an
inhibitor of OATPs and NTCP.
Predicted median AUC and Cmax ratios of rosuvastatin
(10 mg multiple dose) following co-administration of
cyclosporine (200 mg twice daily) for 10 days ranged from
1.45 to 1.68 and 2.73 to 3.62, respectively, for the ten trials.
Although clinical data from a crossover study design in
HVs were not available for direct comparison, rosuvastatin
pharmacokinetic parameters had been assessed in an open-
label trial involving stable heart transplant recipients
([6 months after transplant) on an anti-rejection regimen
including cyclosporine [21]. In these patients taking rosu-
vastatin 10 mg for 10 days, geometric mean values and
percentage coefficient of variation for steady-state AUC24
and Cmax were 284 ngh/mL (31.3 %) and 48.7 ng/mL
(47.2 %), respectively. In controls (historical data AUC24
and Cmax from 21 HVs taking rosuvastatin 10 mg), these
values were 40.1 ngh/mL (39.4 %) and 4.58 ng/mL
(46.9 %), respectively [21]. Thus, compared with control
values, AUC24 and Cmax values were increased 7.1- and
10.6-fold, respectively, in transplant recipients. The pre-
dicted increase in exposure of rosuvastatin following co-
administration of cyclosporine in virtual HV subjects is
lower than observed in vivo.
Recently, Gertz and co-workers [77] developed a PBPK
model to predict the inhibitory effects of cyclosporine and its
mono-hydroxylated metabolite on intestinal CYP3A4
metabolism and uptake and efflux transporters. Their model
indicated that cyclosporine had the highest impact on the
liver uptake transporters and minimal impact on hepatic
efflux and metabolism. Inclusion of the cyclosporine
metabolite had little impact on the predicted interaction with
liver uptake transporters. Thus, the fact that we did not
consider the impact of the cyclosporine metabolite does not
account for the under-prediction of the tDDIs with rosu-
vastatin seen in our study. However, it should be noted that
other disease-related factors may contribute to increased
exposure of rosuvastatin in patients. In addition, the expo-
sure of cyclosporine itself may differ between heart trans-
plant patients and the virtual HV subjects. Despite the
limitations and lack of clinical data for direct comparison,
the PBPK model presented here for rosuvastatin is sensitive
to inhibition of the transporters OATP1B1, OATP1B3,
OATP2B1, NTCP and BCRP by cyclosporine. The devel-
oped PBPK model also predicts the intracellular liver con-
centration of rosuvastatin in the presence and absence of the
inhibitor. As Fig. 4 shows, the predicted magnitude of
interaction within the tissue can be different to that obtained
in the plasma. Depending on the drug characteristics, the
difference can be significant. Such knowledge can be
a
b
Fig. 3 a Simulated plasma concentration–time profiles of rosuvast-
atin on day 10 in the absence and presence of cyclosporine (200 mg
twice daily) in healthy volunteers following the oral administration of
rosuvastatin 10 mg (multiple dose). b Simulated versus observed
plasma concentration–time profile of cyclosporine (200 mg twice
daily) on day 10. The thin grey lines represent simulated individual
trials (ten trials of ten subjects) and the thick black lines are the
simulated mean of the healthy volunteer population (n = 100)
without (solid lines) and with interaction (dashed lines). The circles
denote mean values from the clinical studies for rosuvastatin [21] and
for cyclosporine [86]
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valuable, especially when liver toxicity is an issue for some
drugs or when the site of drug action is within the liver, in the
case of statins. Indeed, it can only increase our understanding
of the drug response and its variability [23].
Given the complexity of processes involved in the trans-
port of drugs into cells, obtaining accurate kinetic parameters
from in vitro assays is very challenging. Recently, model-
based data analysis of in vitro assays has attracted more
attention and new methods and data analysis techniques are
proposed; for more detail see previous publications [76, 78–
80]. The functional translation of some SLC effects using
IVIVE approaches is challenging due to the existence of
several binding sites [81], the possible time-dependent
inhibition for some SLCs [57, 77] and the limitations of
apparent in vitro kinetic parameter measurements [82].
Adding to this complexity, in order to have a robust PBPK
model, the relative contributions of both active and passive
components need to be assigned correctly. In addition, the
active component itself can be a sum of different uptake and
efflux transporters working in parallel or against each other
on the same membrane. Thus, the fractional contribution of
each transporter (ft) to the global transport is as important as
the ‘fm’ (the fraction of a drug metabolized by an enzyme)
for CYP enzymes in the prediction of interactions involving
metabolism. For our PBPK model of rosuvastatin, a global
hepatic uptake was fitted using intravenous clinical data and
the relative contributions of OATP1B1, OATP1B3
(OATP2B1), NTCP and BCRP were assigned based on
in vitro data. Our model has also successfully been applied to
predict the disposition and DDIs of other drugs such as
repaglinide and pravastatin [40, 58, 83, 84].
Transporters’ ‘ft’ values are used to predict tDDIs in a
manner similar to that used for CYP enzymes. These
fraction values have been used in static equations with
different degrees of success depending on the applied
assumptions [84, 85]. In some cases it is assumed that the
transport process occurs exclusively via a particular uptake
transporter, ignoring the potential contribution of passive
diffusion or other transporters or involvement of metabo-
lism. The static equations cannot account for the time-
varying nature of the substrate and inhibitor concentrations
and assume constant values. Further, since these models
cannot estimate the relevant concentrations at the transport
site, surrogate concentrations such as plasma or average gut
concentration (highest oral dose diluted in 250 mL) are
used. These assumptions often increase the possibility of
encountering false positive predictions and may lead to
unnecessary clinical studies being conducted. Given the
complexity of the processes involved in metabolism and
transport interplay, dynamic models for determining DDIs
are preferable. However, in some cases during the early
stages of drug development, static equations, if applied
with correct assumptions, may provide a reasonable esti-
mate of tDDIs.
5 Conclusions
Incorporation of transporters within PBPK models can
provide some insight into their role in drug disposition and
lead to improved understanding of the drug response and
its variability. In particular, when these models account for
a b
Fig. 4 Simulated unbound liver concentrations in a extracellular
(CuEW) and b intracellular (CuIW) compartments of rosuvastatin on
day 10 in the absence and presence of cyclosporine (200 mg twice
daily) in healthy volunteers following the oral administration of
rosuvastatin 10 mg (multiple dose). The grey and black lines
represent the mean concentrations for the simulated population in
the absence and presence of cyclosporine, respectively
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mDDIs and tDDIs simultaneously for multiple moieties
they become very powerful tools for investigating complex
cases that can occur in clinical practice. Although there are
still gaps in our knowledge regarding physiological data
such as reliable absolute abundance/activity data for
transporters, observed clinical data can be used to estimate
the unknown model parameters and, once validated, the
model can then be applied prospectively, to predict tDDIs.
Application of these models can aid in making informed
decisions on the design of clinical studies and give an
indication of whether such studies are needed. Indeed,
successful application of these models (e.g. Varma et al.
[58, 83]) demonstrates the value and impact of model-
based drug development in the pharmaceutical industry.
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